OncoMatch/Clinical Trials/NCT07043270
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Is NCT07043270 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nab-paclitaxel + Gemcitabine and modified FOLFIRINOX (mFOLFIRINOX) for pancreas adenocarcinoma.
Treatment: Nab-paclitaxel + Gemcitabine · modified FOLFIRINOX (mFOLFIRINOX) — The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Excluded: DPYD poor metabolizer genotype
Excluded: PALB2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Any prior receipt of chemotherapy or radiation therapy for PDAC.
Cannot have received: radiation therapy
Any prior receipt of chemotherapy or radiation therapy for PDAC.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 2,500/mm3; Platelet count < 100,000/mm3; Hemoglobin < 7 g/dL [excluded]
Kidney function
Creatinine > 1.5 x upper limit of normal (ULN) [excluded]
Liver function
Total bilirubin > 1.5 x ULN; AST/ALT > 5 x ULN [excluded]
Any of the following baseline laboratory abnormalities: Absolute neutrophil count (ANC) < 2,500/mm3; Platelet count < 100,000/mm3; Hemoglobin < 7 g/dL; Creatinine > 1.5 x upper limit of normal (ULN); Total bilirubin > 1.5 x ULN; AST/ALT > 5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07043270 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages